Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro

Oncology. Jan-Feb 1997;54(1):48-54. doi: 10.1159/000227661.

Abstract

To clarify the significance of the Fas antigen (Ag) in gynecologic tumors, its expression in gynecologic cancer cell lines was examined. The Fas Ag was expressed in 6 of 15 cell lines. Five of 8 ovarian cancer cell lines but none of 4 choriocarcinoma cell lines expressed the Fas Ag. In drug-resistant cell lines derived from one of the Fas-positive cells, its expression was not lost after development of resistance to cisplatin, SN-38 or etoposide, but its expression was absent in the cell line resistant to Adriamycin. The effect of the anti-Fas antibody (Ab) was then studied. Apoptosis was induced in 7 of 9 Fas-positive cell lines, whereas the remaining two cell lines were unaffected. Furthermore, the combination effect of the anti-Fas Ab and drugs was examined in an ovarian cancer cell line and its drug-resistant variants, and a synergistic effect was observed. These results suggest important roles of the Fas Ag in ovarian cancer and the potential for overcoming drug resistance by a combination of the anti-Fas Ab and various drugs.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Combined Modality Therapy
  • Female
  • Gene Expression Regulation, Neoplastic
  • Genital Neoplasms, Female / therapy
  • Humans
  • Immunotherapy / methods*
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / therapy*
  • Tumor Cells, Cultured
  • fas Receptor / immunology*

Substances

  • fas Receptor